Sharemaestro company-news research for Roivant Sciences Ltd (ROIV), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NASDAQ United States Provisional evidence

Company news sentiment

Latest ROIV news and sentiment

Roivant Sciences Ltd

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research Options activity RSS feed
Latest weekly closeUSD 35.72week of 2 Oct 2026
Main news subjectMarket update82/100 share of current news
News data statusPartial27 duplicate stories removed

Current company news

Early balanced news score

46 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone65/100 Published 30-day score52/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class Stocktwits · 08 Oct 2026 17:33

What supports the score

Direct evidence

46 current stories are mapped specifically to ROIV.

Source breadth

The score uses 9 publishers rather than depending on one outlet.

What limits the score

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.124.

Confidence

Confidence is 21/100, below the threshold for a firm score.

52/100
News scoreEarly balanced news score
21/100
Confidencethin evidence
100%/100
Company news46 company stories
91/100
Story agreement9/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence · gaps mean no reading
12 Sep: 2 stories13 Sep: 1 stories15 Sep: 2 stories16 Sep: 1 stories17 Sep: 1 stories18 Sep: 6 stories21 Sep: 1 stories22 Sep: 2 stories23 Sep: 7 stories25 Sep: 1 stories26 Sep: 1 stories28 Sep: 4 stories29 Sep: 1 stories30 Sep: 2 stories01 Oct: 2 stories02 Oct: 1 stories03 Oct: 6 stories05 Oct: 1 stories07 Oct: 2 stories08 Oct: 1 stories 12 Sep: tone 79, 2 stories13 Sep: tone 55, 1 stories15 Sep: tone 45, 2 stories16 Sep: tone 57, 1 stories17 Sep: tone 74, 1 stories18 Sep: tone 55, 6 stories21 Sep: tone 57, 1 stories22 Sep: tone 56, 2 stories23 Sep: tone 50, 7 stories25 Sep: tone 55, 1 stories26 Sep: tone 74, 1 stories28 Sep: tone 58, 4 stories29 Sep: tone 50, 1 stories30 Sep: tone 50, 2 stories01 Oct: tone 50, 2 stories02 Oct: tone 50, 1 stories03 Oct: tone 47, 6 stories05 Oct: tone 50, 1 stories07 Oct: tone 50, 2 stories08 Oct: tone 50, 1 stories 100500
11 Sep26 Sep10 Oct
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence2
0.124 after freshness weighting
Source breadth100
9 independent publishers
Company relevance100
share tied directly to this company
Freshness24
recency-weighted evidence
Agreement91
how closely stories agree
Publisher mix49
less reliance on one publisher

Price and news history

Weekly price and news-score history

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

26 completed price weeks15 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
10 Apr 2026: close 28.21, indexed 100.017 Apr 2026: close 29.83, indexed 105.724 Apr 2026: close 27.41, indexed 97.201 May 2026: close 27.83, indexed 98.708 May 2026: close 28.56, indexed 101.215 May 2026: close 29.29, indexed 103.822 May 2026: close 29.96, indexed 106.229 May 2026: close 29.99, indexed 106.305 Jun 2026: close 28.58, indexed 101.312 Jun 2026: close 30.04, indexed 106.519 Jun 2026: close 31.43, indexed 111.426 Jun 2026: close 34.07, indexed 120.803 Jul 2026: close 35.13, indexed 124.510 Jul 2026: close 35.97, indexed 127.517 Jul 2026: close 34.51, indexed 122.324 Jul 2026: close 35.01, indexed 124.131 Jul 2026: close 33.91, indexed 120.207 Aug 2026: close 36.34, indexed 128.814 Aug 2026: close 36.2, indexed 128.321 Aug 2026: close 36.3, indexed 128.728 Aug 2026: close 34.71, indexed 123.004 Sep 2026: close 34.93, indexed 123.811 Sep 2026: close 40.82, indexed 144.718 Sep 2026: close 39.77, indexed 141.025 Sep 2026: close 35.8, indexed 126.902 Oct 2026: close 35.72, indexed 126.6 26 Jun 2026: news score 50, close 34.07, 5 stories5003 Jul 2026: news score 50, close 35.13, 9 stories10 Jul 2026: news score 50, close 35.97, 12 stories17 Jul 2026: news score 51, close 34.51, 17 stories5124 Jul 2026: news score 54, close 35.01, 23 stories31 Jul 2026: news score 49, close 33.91, 36 stories07 Aug 2026: news score 53, close 36.34, 52 stories5314 Aug 2026: news score 51, close 36.2, 57 stories21 Aug 2026: news score 53, close 36.3, 68 stories28 Aug 2026: news score 59, close 34.71, 69 stories5904 Sep 2026: news score 59, close 34.93, 64 stories11 Sep 2026: news score 63, close 40.82, 57 stories18 Sep 2026: news score 61, close 39.77, 52 stories6125 Sep 2026: news score 56, close 35.8, 54 stories02 Oct 2026: news score 55, close 35.72, 56 stories55 Price index 150.4 120.9 91.5 News score 100 50 0
10 Apr07 Jul02 Oct
Weekly close, indexedSentiment score
26-week price+26.6%latest close 35.72
News score change+5first to latest comparable week
One-week response-0.2%Price digesting
Fair-value position+112.5%Materially above fair value
WeekNews scoreCloseWeekly move
02 Oct 202655USD 35.72-0.2%
25 Sep 202656USD 35.8-10.0%
18 Sep 202661USD 39.77-2.6%
11 Sep 202663USD 40.82+16.9%
04 Sep 202659USD 34.93+0.6%
28 Aug 202659USD 34.71-4.4%
21 Aug 202653USD 36.3+0.3%
14 Aug 202651USD 36.2-0.4%
Provisional evidence

News subjects

What is shaping the score

Market update
Market update4930 stories · 65%
Earnings539 stories · 20%
Analyst action723 stories · 7%
Regulatory and legal583 stories · 7%
Guidance501 stories · 2%

Source mix

Where the evidence comes from

49/100 independence
Stock Titan4613 stories · 28%
Stocktwits554 stories · 9%
Insider Monkey553 stories · 7%
Yahoo! Finance Canada503 stories · 7%
Investing.com Nigeria503 stories · 7%
Moomoo642 stories · 4%
Simply Wall Street502 stories · 4%

Recurring subjects

Subjects appearing most often

Current evidence
Life Sciences25Financial Markets18Finance11Earnings11Clinical Trials5Biotech4Pharma2Fda Approval2Revenue Growth1Pulmonary Disease1

Earlier readings

How the score has changed

52 comparable readings · 71 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+349 to 52 · Broadly stable
Observed range49–6550 is the neutral baseline
Evidence depth46stories at latest stored reading · +13
Confidence20/100Provisional · -8
30 Jul50 neutral10 Oct 09:13
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
10 Oct 09:1352+020/100 (-1)46 (-4)Provisional
08 Oct 23:5952+021/100 (-1)50 (-10)Provisional
07 Oct 23:5952-122/100 (-2)60 (0)Provisional
05 Oct 23:5953-124/100 (-4)60 (-2)Provisional
03 Oct 23:5954-128/100 (+2)62 (+6)Provisional
02 Oct 23:5955-126/100 (-2)56 (+1)Provisional
01 Oct 23:5956+028/100 (-1)55 (+1)Provisional
30 Sep 23:5956-129/100 (-2)54 (0)Provisional

Evidence behind the direction

What drives this reading?

12 directional stories · 9 publisher groups

Shares of weighted directional evidence in 46 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.

Which subjects lean each way

A subject can carry both supportive and cautious news.

SubjectCautious ← 0 → Constructive
Regulatory and legal1 story
0.0%70.2%
Earnings2 stories
0.0%10.6%
Analyst action3 stories
0.0%9.8%
Market update6 stories
9.2%0.1%

Each side uses the same scale: 0–70.2% of the retained directional evidence.

Where the influence comes from

70.2%largest publisher share

A concentrated reading can depend heavily on one publisher.

Quiver Quantitative1 story70.2%
Stock Titan2 stories9.1%
Moomoo1 story7.4%
Simply Wall St.1 story6.3%
Stocktwits3 stories4.3%
Remaining publishers4 stories2.7%

Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.

Source headlines

The news behind the score

Showing 1-30 of 46

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

Stocktwits
—Unscored
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Published
08 Oct 2026 17:33
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 1.7d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
Yahoo! Finance Canada
—Unscored
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Published
07 Oct 2026 21:30
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 2.5d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
Simply Wall Street
—Unscored
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Published
07 Oct 2026 01:31
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 3.3d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
Benzinga
—Unscored

Roivant Sciences held its Q1 2027 earnings call, discussing a quiet quarter but anticipating a busy second half with the expected launch of brepocitinib by September. The company highlighted progress in its pipeline, including the initiation of a Phase 3 study for brepocitinib in cutaneou…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Roivant Sciences held its Q1 2027 earnings call, discussing a quiet quarter but anticipating a busy second half with the expected launch of brepocitinib by September. The company highlighted progress in its pipeline, including the initiation of a Phase 3 study for brepocitinib in cutaneous sarcoidosis and ongoing enrollment for lichen planopilaris. Financially, Roivant reported $950 million from a Moderna settlement, approximately $200 million in R&D expenses, and nearly $100 million in non-GAAP G&A expenses, with a cash position of just under $4 billion.

Published
05 Oct 2026 11:04
News subject
Earnings
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 4.9d old
Text assessed
Stored article
Duplicates
1 consolidated
EarningsFinanceLife Sciences
Stock Traders Daily
—Unscored
Market updateNot used in direction

How (ROIV) Movements Inform Risk Allocation Models

This article analyzes Roivant Sciences Ltd. (NASDAQ: ROIV) stock, highlighting divergent sentiment across time horizons and a mid-channel oscillation pattern. It presents an exceptional 28.8:1 risk-reward setup, targeting an 8.2% gain versus 0.3% risk. The analysis includes AI-generated t…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

This article analyzes Roivant Sciences Ltd. (NASDAQ: ROIV) stock, highlighting divergent sentiment across time horizons and a mid-channel oscillation pattern. It presents an exceptional 28.8:1 risk-reward setup, targeting an 8.2% gain versus 0.3% risk. The analysis includes AI-generated trading strategies for different risk profiles, offering position trading, momentum breakout, and risk hedging approaches.

Published
03 Oct 2026 17:28
News subject
Market update
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 6.7d old
Text assessed
Stored article
Duplicates
1 consolidated
FinanceFinancial MarketsLife Sciences
Stock Titan
—Unscored

Roivant Sciences Ltd.'s President & CIO, Mayukh Sukhatme, had 46,879 common shares withheld on September 30, 2026, to cover tax withholding obligations associated with the vesting of previously granted Restricted Stock Units (RSUs). The shares were valued at $36.57 each, amounting to appr…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Roivant Sciences Ltd.'s President & CIO, Mayukh Sukhatme, had 46,879 common shares withheld on September 30, 2026, to cover tax withholding obligations associated with the vesting of previously granted Restricted Stock Units (RSUs). The shares were valued at $36.57 each, amounting to approximately $1.71 million. Following this transaction, Sukhatme directly holds 18,583,860 common shares in the company.

Published
03 Oct 2026 12:34
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 6.9d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
FinanceLife Sciences
Stock Titan
40/100 tone

Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd. (ROIV), exercised options for 200,000 common shares at $3.85 per share and subsequently sold all 200,000 shares at a weighted average price of $36.62 per share on September 30, 2026. These transactions were executed under a …

9% of directional evidence Medium story strength
Scoring detailsDirect company coverage

Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd. (ROIV), exercised options for 200,000 common shares at $3.85 per share and subsequently sold all 200,000 shares at a weighted average price of $36.62 per share on September 30, 2026. These transactions were executed under a Rule 10b5-1 trading plan adopted in March 2025. Following these sales, Venker's direct stock-option position was 3,644,834 shares and 1,599,154 common shares.

Published
03 Oct 2026 12:34
News subject
Market update
Why this score
Institutional or insider selling
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 37/100
30-day weight
9% of directional evidence · 6.9d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
FinanceFinancial MarketsLife Sciences
Moomoo
—Unscored

An officer at Roivant Sciences (ROIV.US) recently sold a significant amount of common stock, totaling US$7.32 million. This transaction provides insight into insider activity at the company.

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

An officer at Roivant Sciences (ROIV.US) recently sold a significant amount of common stock, totaling US$7.32 million. This transaction provides insight into insider activity at the company.

Published
03 Oct 2026 05:28
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 7.2d old
Text assessed
Stored article
Duplicates
1 consolidated
FinanceFinancial MarketsLife Sciences
Investing.com Nigeria
—Unscored

This article reports on a Form 4 filing for Roivant Sciences Ltd. related to activity on October 2nd. The content is brief and primarily serves as a notification of the filing, with no further details provided within the article itself. It includes the stock symbol ROIV.

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

This article reports on a Form 4 filing for Roivant Sciences Ltd. related to activity on October 2nd. The content is brief and primarily serves as a notification of the filing, with no further details provided within the article itself. It includes the stock symbol ROIV.

Published
03 Oct 2026 03:02
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 7.3d old
Text assessed
Stored article
Duplicates
1 consolidated
Financial Markets
Stock Titan
—Unscored

Frank Torti, President and Vant Chair of Roivant Sciences (ROIV), acquired 40,309 common shares on September 30, 2026. This acquisition was a result of the net settlement of previously granted Restricted Stock Units (RSUs) to cover tax withholding obligations. Following this transaction, …

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Frank Torti, President and Vant Chair of Roivant Sciences (ROIV), acquired 40,309 common shares on September 30, 2026. This acquisition was a result of the net settlement of previously granted Restricted Stock Units (RSUs) to cover tax withholding obligations. Following this transaction, Torti's reported holdings in Roivant Sciences totaled 13,495,893 common shares, with the acquired shares valued at $36.57 each.

Published
03 Oct 2026 01:28
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 7.3d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
FinanceFinancial MarketsLife Sciences
Stock Titan
—Unscored

Roivant Sciences Ltd. CEO Matthew Gline reported the disposition of 76,171 common shares on September 30, 2026, to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs). The shares were valued at $36.57 each. Following this transaction, Gline direc…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Roivant Sciences Ltd. CEO Matthew Gline reported the disposition of 76,171 common shares on September 30, 2026, to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs). The shares were valued at $36.57 each. Following this transaction, Gline directly holds 16,583,774 common shares in the company.

Published
02 Oct 2026 23:28
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 7.4d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
EarningsFinanceLife Sciences
Benzinga
—Unscored

Roivant Sciences (NASDAQ: ROIV) has significantly outperformed the market over the last five years, with an annualized return of 39.09%. An investment of $1000 in ROIV five years ago would now be worth $4,366.54, highlighting the power of compounded returns. The company currently has a ma…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Roivant Sciences (NASDAQ: ROIV) has significantly outperformed the market over the last five years, with an annualized return of 39.09%. An investment of $1000 in ROIV five years ago would now be worth $4,366.54, highlighting the power of compounded returns. The company currently has a market capitalization of $25.77 billion.

Published
01 Oct 2026 22:56
News subject
Market update
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 8.4d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
EarningsFinancial MarketsLife Sciences
Investing.com Nigeria
—Unscored

This article reports on a Form 144 filing by Roivant Sciences Ltd. on October 1st. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The article provides the date of the filing and mentions Roivant Sciences Ltd. (ROIV) with a slight s…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

This article reports on a Form 144 filing by Roivant Sciences Ltd. on October 1st. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The article provides the date of the filing and mentions Roivant Sciences Ltd. (ROIV) with a slight stock percentage change.

Published
01 Oct 2026 18:26
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 8.6d old
Text assessed
Stored article
Duplicates
1 consolidated
FinanceFinancial MarketsLife Sciences
Stock Titan
—Unscored

Roivant Sciences Ltd. officer Eric Venker has proposed selling 200,000 common shares worth $7.32 million through Rockefeller Financial LLC on September 30, 2026, under a Rule 10b5-1 trading plan. This proposed sale follows previous sales in July and August 2026, including a significant sa…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Roivant Sciences Ltd. officer Eric Venker has proposed selling 200,000 common shares worth $7.32 million through Rockefeller Financial LLC on September 30, 2026, under a Rule 10b5-1 trading plan. This proposed sale follows previous sales in July and August 2026, including a significant sale of 200,000 shares for $7.15 million on August 28, 2026. The filing provides details on the acquisition of the securities through an options exercise from April 20, 2022.

Published
30 Sep 2026 20:22
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 9.5d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
Financial MarketsLife Sciences
Yahoo! Finance Canada
—Unscored
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Published
30 Sep 2026 16:33
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 9.7d old
Text assessed
Stored headline only
Duplicates
1 consolidated
TradingKey
—Unscored

Analysts have provided a price target and forecast for Roivant Sciences Ltd (ROIV). Based on 12 analysts, the average target price is $46.482, representing a potential upside of 29.84%. The stock currently has a "Buy" trend with 6 Buy ratings and 1 Hold rating in the last month, and finan…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Analysts have provided a price target and forecast for Roivant Sciences Ltd (ROIV). Based on 12 analysts, the average target price is $46.482, representing a potential upside of 29.84%. The stock currently has a "Buy" trend with 6 Buy ratings and 1 Hold rating in the last month, and financial forecasts for EPS and revenue are also provided.

Published
29 Sep 2026 09:31
News subject
Guidance
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 11.0d old
Text assessed
Stored article
Duplicates
1 consolidated
EarningsFinancial MarketsLife Sciences
Quiver Quantitative
67/100 tone

Roivant Sciences (ROIV) saw a 3.7% increase in its stock price, attributed to continued investor enthusiasm following positive Phase 2 clinical data for mosliciguat, recent FDA approval for LISRAYA, and bullish analyst sentiment. Although there was no new company-specific announcement, th…

70.2% of directional evidence Medium story strength
Scoring detailsDirect company coverage

Roivant Sciences (ROIV) saw a 3.7% increase in its stock price, attributed to continued investor enthusiasm following positive Phase 2 clinical data for mosliciguat, recent FDA approval for LISRAYA, and bullish analyst sentiment. Although there was no new company-specific announcement, the gain likely reflects sustained momentum and positioning for upcoming pipeline milestones expected in the second half of 2026. Insider selling activity has been significant over the past six months, while hedge funds show mixed but substantial position changes.

Published
28 Sep 2026 17:36
News subject
Regulatory and legal
Why this score
Fda Approval
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 52/100
30-day weight
70.2% of directional evidence · 11.7d old
Text assessed
Stored article
Duplicates
1 consolidated
Financial MarketsLife Sciences
MarketBeat
—Unscored

Roivant Sciences is preparing for the launch of LISRAYA, a newly approved drug for dermatomyositis, while also advancing key pipeline programs. CEO Matthew Gline highlighted upcoming clinical data for brepocitinib (LISRAYA) in non-infectious uveitis and Immunovant’s IMVT-1402 in rheumatoi…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Roivant Sciences is preparing for the launch of LISRAYA, a newly approved drug for dermatomyositis, while also advancing key pipeline programs. CEO Matthew Gline highlighted upcoming clinical data for brepocitinib (LISRAYA) in non-infectious uveitis and Immunovant’s IMVT-1402 in rheumatoid arthritis, cutaneous lupus erythematosus, and Graves’ disease. Additionally, the company is expanding its pulmonary hypertension program with mosliciguat, following positive Phase II results.

Published
28 Sep 2026 08:02
News subject
Market update
Why this score
Positive financial language
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 12.0d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
EarningsLife Sciences
Investing.com Australia
—Unscored

This article from Investing.com is a regulatory filing update, specifically a Form 4, for Roivant Sciences Ltd., dated September 28. It indicates insider transaction activity for the company. The content primarily serves as a placeholder for the filing information, with little additional …

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

This article from Investing.com is a regulatory filing update, specifically a Form 4, for Roivant Sciences Ltd., dated September 28. It indicates insider transaction activity for the company. The content primarily serves as a placeholder for the filing information, with little additional detail provided within the article itself.

Published
28 Sep 2026 05:58
News subject
Regulatory and legal
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 12.1d old
Text assessed
Stored article
Duplicates
1 consolidated
Financial MarketsLife Sciences
Investing.com India
—Unscored

This article announces the filing of a Form 4 for Roivant Sciences Ltd. on September 27. It contains minimal actual content beyond the title, serving as a placeholder for the regulatory filing information. The piece includes various financial market data, news headlines, and stock perform…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

This article announces the filing of a Form 4 for Roivant Sciences Ltd. on September 27. It contains minimal actual content beyond the title, serving as a placeholder for the regulatory filing information. The piece includes various financial market data, news headlines, and stock performance figures, typical of an Investing.com page.

Published
28 Sep 2026 02:41
News subject
Regulatory and legal
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 12.3d old
Text assessed
Stored article
Duplicates
1 consolidated
Financial MarketsLife Sciences
Moomoo
74/100 tone

Bernstein has initiated coverage on Roivant Sciences (ROIV.US) with a Buy rating. The firm has set a price target of $41 for the company's stock. This indicates a positive outlook from Bernstein regarding Roivant Sciences' future performance.

7.4% of directional evidence Medium story strength
Scoring detailsDirect company coverage

Bernstein has initiated coverage on Roivant Sciences (ROIV.US) with a Buy rating. The firm has set a price target of $41 for the company's stock. This indicates a positive outlook from Bernstein regarding Roivant Sciences' future performance.

Published
26 Sep 2026 03:21
News subject
Analyst action
Why this score
Buy Rating
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 50/100
30-day weight
7.4% of directional evidence · 14.2d old
Text assessed
Stored article
Duplicates
1 consolidated
Financial MarketsLife Sciences
Insider Monkey
—Unscored

Roivant Sciences Ltd. (NASDAQ: ROIV) saw its shares jump after reporting positive Phase 2 results for mosliciguat, a treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The drug met both primary and secondary endpoints, leading Roivant to initiate a Ph…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Roivant Sciences Ltd. (NASDAQ: ROIV) saw its shares jump after reporting positive Phase 2 results for mosliciguat, a treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The drug met both primary and secondary endpoints, leading Roivant to initiate a Phase 3 study. This development positions mosliciguat as another significant late-stage asset for the company, following the recent FDA approval of Lisraya.

Published
25 Sep 2026 09:55
News subject
Earnings
Why this score
Positive market reaction
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 15.0d old
Text assessed
Stored article
Duplicates
2 consolidated
Clinical TrialsEarningsFda ApprovalLife SciencesPharma
Investing.com Nigeria
—Unscored

This Investing.com article reports on a Form 4 filing for Roivant Sciences Ltd. related to September 22. It mentions the company's stock symbol ROIV and notes that no comments have been made on the filing. The article appears to be a brief financial news update providing minimal detail be…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

This Investing.com article reports on a Form 4 filing for Roivant Sciences Ltd. related to September 22. It mentions the company's stock symbol ROIV and notes that no comments have been made on the filing. The article appears to be a brief financial news update providing minimal detail beyond the filing's existence.

Published
23 Sep 2026 20:24
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 16.5d old
Text assessed
Stored article
Duplicates
1 consolidated
Financial MarketsLife Sciences
InvestorsHub
43/100 tone
0.1% of directional evidence Low story strength
Scoring detailsDirect company coverage
Published
23 Sep 2026 12:12
News subject
Market update
Why this score
Negative financial language
Company focus
Shared story · 78%
How it is used
Direct company coverage
Story strength
Low · 26/100
30-day weight
0.1% of directional evidence · 16.9d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
MT Newswires
—Unscored
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Published
23 Sep 2026 11:47
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 16.9d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
GlobeNewswire
—Unscored

Roivant Sciences Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from …

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Roivant Sciences Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant's internal bar to continue development of IMVT-1402 in CLE IMVT-1402 demonstrated a favorable safety and tolerability profile, consi

Published
23 Sep 2026 11:00
News subject
Earnings
Why this score
Positive financial language
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 16.9d old
Text assessed
Available headline and article text
Duplicates
3 consolidated
Autoimmune DiseasesBiotechClinical Trials
Simply Wall Street
—Unscored

Roivant Sciences (ROIV) has garnered attention due to positive Phase 2 PHocus results for mosliciguat, showing a significant reduction in pulmonary vascular resistance. Despite this, the stock trades below analyst targets, and a narrative suggests it is overvalued, citing risks related to…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Roivant Sciences (ROIV) has garnered attention due to positive Phase 2 PHocus results for mosliciguat, showing a significant reduction in pulmonary vascular resistance. Despite this, the stock trades below analyst targets, and a narrative suggests it is overvalued, citing risks related to IP litigation, competition in the autoimmune space, monetization strategy, and a conglomerate discount. The article highlights both the potential upsides from clinical success and the market's current cautious valuation of the company.

Published
23 Sep 2026 09:55
News subject
Earnings
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 17.0d old
Text assessed
Stored article
Duplicates
1 consolidated
EarningsFinancial MarketsLife Sciences
Stock Titan
—Unscored

Roivant Sciences' CFO, Richard Pulik, had 2,129 common shares withheld on September 20, 2026, to cover tax withholding obligations from vested Restricted Stock Units (RSUs). This transaction was a net share settlement, not an open-market sale, and resulted in Pulik directly holding 269,68…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Roivant Sciences' CFO, Richard Pulik, had 2,129 common shares withheld on September 20, 2026, to cover tax withholding obligations from vested Restricted Stock Units (RSUs). This transaction was a net share settlement, not an open-market sale, and resulted in Pulik directly holding 269,681 common shares. The shares were valued at $39.77 each for tax purposes.

Published
23 Sep 2026 09:55
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 17.0d old
Text assessed
Stored article
Duplicates
1 consolidated
FinanceLife Sciences
Yahoo! Finance Canada
—Unscored

This article provides comprehensive financial data for Roivant Sciences Ltd. (ROIV), including its current stock price, historical performance, key financial metrics, and analyst insights. It details the company's biopharmaceutical focus, outlining its clinical product candidates and deli…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

This article provides comprehensive financial data for Roivant Sciences Ltd. (ROIV), including its current stock price, historical performance, key financial metrics, and analyst insights. It details the company's biopharmaceutical focus, outlining its clinical product candidates and delivery platforms. The report also compares ROIV's performance against the S&P 500 and presents earnings trends and analyst price targets.

Published
23 Sep 2026 07:38
News subject
Earnings
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 17.1d old
Text assessed
Stored article
Duplicates
1 consolidated
EarningsFinancial MarketsLife Sciences
Insider Monkey
56/100 tone

Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to commercialization. Stifel initiated coverage of Roivant with a Buy rating and a $51 price target on September 16. The target implied a …

1.2% of directional evidence Low story strength
Scoring detailsDirect company coverage

Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to commercialization. Stifel initiated coverage of Roivant with a Buy rating and a $51 price target on September 16. The target implied a roughly 29% upside from the stock price at that time. Stifel argued that Roivant offers multiple late-stage opportunities across specialty autoimmune and pulmonary diseases. The firm projects around $9 billion in ownership-adjusted sales for Roivant by 2037. Can Roivant turn its multi-asset strategy into long-

Published
22 Sep 2026 10:27
News subject
Analyst action
Why this score
Analyst upgrade
Company focus
Shared story · 78%
How it is used
Direct company coverage
Story strength
Low · 26/100
30-day weight
1.2% of directional evidence · 17.9d old
Text assessed
Stored article
Duplicates
2 consolidated
BiotechClinical TrialsFda ApprovalPrice TargetRevenue Growth

Earlier company news

ROIV news archive

136 older headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Older news is kept in the archive

There are 136 older ROIV headlines. Open one page at a time when you need them.

Open older archive

Provider matches checked

Provider mentions not used in the score

Showing 1-12 of 12

A news provider linked these stories to ROIV, but the headline and available text are not mainly about Roivant Sciences Ltd. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

MarketBeat
19Aug 2026

Mayukh Sukhatme, an insider at Roivant Sciences (NASDAQ:ROIV), sold 284,707 shares of the company's stock for approximately $10.3 million on August 17th, 2026, reducing his position by 1.51%. This follows two other recent sales by Sukhatme. Despite these insider sales, analysts maintain a…

Article detailsWhy it was excluded

Mayukh Sukhatme, an insider at Roivant Sciences (NASDAQ:ROIV), sold 284,707 shares of the company's stock for approximately $10.3 million on August 17th, 2026, reducing his position by 1.51%. This follows two other recent sales by Sukhatme. Despite these insider sales, analysts maintain a "Moderate Buy" consensus rating for ROIV, with the stock trading near its 52-week high after beating quarterly EPS expectations but missing revenue estimates.

Published
19 Aug 2026 02:13
Provider record
alphavantage
Use in sentiment
Not scored
Reason
Company is not the main subject
Duplicates
1 consolidated
EarningsFinancial MarketsLife Sciences
MarketBeat
16Aug 2026

Royal Bank of Canada significantly reduced its stake in Roivant Sciences Ltd. by 82.1% in the first quarter, selling over 500,000 shares. Despite this, institutional investors still hold a substantial 64.76% of the company, and analysts generally maintain a "Moderate Buy" rating with a ta…

Article detailsWhy it was excluded

Royal Bank of Canada significantly reduced its stake in Roivant Sciences Ltd. by 82.1% in the first quarter, selling over 500,000 shares. Despite this, institutional investors still hold a substantial 64.76% of the company, and analysts generally maintain a "Moderate Buy" rating with a target price of $35.14. Insider selling also occurred, with key directors divesting shares, although insiders collectively still own 8.8% of the stock.

Published
16 Aug 2026 10:11
Provider record
alphavantage
Use in sentiment
Not scored
Reason
Company is not the main subject
Duplicates
1 consolidated
FinanceFinancial MarketsLife Sciences
MarketBeat
16Aug 2026

Empowered Funds LLC significantly increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 1,468.5% in the first quarter, acquiring an additional 267,686 shares to bring its total holdings to 285,915 shares, valued at approximately $7.92 million. Despite this institutional buying, Ro…

Article detailsWhy it was excluded

Empowered Funds LLC significantly increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 1,468.5% in the first quarter, acquiring an additional 267,686 shares to bring its total holdings to 285,915 shares, valued at approximately $7.92 million. Despite this institutional buying, Roivant insiders have sold 2.06 million shares worth about $69.6 million in the last three months. The stock opened at $36.20, near its 52-week high, and analysts maintain a "Moderate Buy" consensus with an average price target of $35.14, although Citigroup recently raised its target to $46.00.

Published
16 Aug 2026 09:11
Provider record
alphavantage
Use in sentiment
Not scored
Reason
Company is not the main subject
Duplicates
1 consolidated
EarningsFinancial MarketsLife Sciences
MarketBeat
15Aug 2026

Handelsbanken Fonder AB significantly increased its stake in Roivant Sciences Ltd. during the second quarter, now holding 177,209 shares valued at $6.27 million. Institutional investors collectively own 64.76% of Roivant's stock, despite recent insider selling totaling approximately 2.06 …

Article detailsWhy it was excluded

Handelsbanken Fonder AB significantly increased its stake in Roivant Sciences Ltd. during the second quarter, now holding 177,209 shares valued at $6.27 million. Institutional investors collectively own 64.76% of Roivant's stock, despite recent insider selling totaling approximately 2.06 million shares. Analysts maintain a "Moderate Buy" rating for ROIV with an average price target of $35.14.

Published
15 Aug 2026 08:41
Provider record
alphavantage
Use in sentiment
Not scored
Reason
Company is not the main subject
Duplicates
1 consolidated
FinanceFinancial MarketsLife Sciences
MarketBeat
25Jul 2026

Allspring Global Investments Holdings LLC initiated a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the first quarter, acquiring 142,134 shares valued at approximately $3.96 million. Institutional ownership of Roivant Sciences is significant, with roughly 64.76% of the stock …

Article detailsWhy it was excluded

Allspring Global Investments Holdings LLC initiated a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the first quarter, acquiring 142,134 shares valued at approximately $3.96 million. Institutional ownership of Roivant Sciences is significant, with roughly 64.76% of the stock held by hedge funds and other institutions, and analysts maintaining an overall "Moderate Buy" rating with an average target price of $33.59. Despite some insider selling, major institutional investors like Morgan Stanley, Vanguard, and UBS have increased their stakes, signaling continued confidence in the biopharmaceutical company.

Published
25 Jul 2026 15:41
Provider record
alphavantage
Use in sentiment
Not scored
Reason
Company is not the main subject
Duplicates
1 consolidated
EarningsFinanceFinancial MarketsIPOLife Sciences
MarketBeat
25Jul 2026

Dimensional Fund Advisors LP decreased its stake in Roivant Sciences Ltd. by 19.2% during the first quarter, selling over 1.7 million shares. Despite this, other institutional investors like Goldman Sachs and UBS AM increased their holdings. Company insiders also sold significant shares, …

Article detailsWhy it was excluded

Dimensional Fund Advisors LP decreased its stake in Roivant Sciences Ltd. by 19.2% during the first quarter, selling over 1.7 million shares. Despite this, other institutional investors like Goldman Sachs and UBS AM increased their holdings. Company insiders also sold significant shares, though institutional ownership remains high at 64.76%.

Published
25 Jul 2026 09:15
Provider record
alphavantage
Use in sentiment
Not scored
Reason
Company is not the main subject
Duplicates
1 consolidated
FinanceFinancial MarketsLife Sciences

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context